AzTrials
AzTrials

Upper Limb AmputationNCT07876115

Cross-Over Study Evaluating the TASKA GEN2 Myoelectric Hand Prosthesis

A study testing TASKA GEN2 Multi-Grip Myoelectric Hand Prosthesis and Michelangelo or I-Limb Ultra multi-grip myoelectric prosthesis in people with Upper Limb Amputation and Transradial Amputation, run by TASKA Prosthetics at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This prospective multicentre randomized cross-over post-market clinical follow-up study compares the TASKA GEN2 multi-grip myoelectric hand prosthesis with marketed comparator prostheses in adults with upper-limb amputation. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
TASKA GEN2 Multi-Grip Myoelectric Hand Prosthesis and Michelangelo or I-Limb Ultra multi-grip myoelectric prosthesis
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteFrance
Study dates
13 Jun 2025to 31 Dec 2026
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patient (>18 years).
  • Unilateral acquired or congenital transradial or transhumeral amputation or elbow disarticulation.
  • Using Michelangelo or I-Limb Ultra prosthesis for >2 months.
  • Prosthesis use >6 hours/day.
  • Written informed consent.

Who cannot join

  • Bilateral upper-limb amputation.
  • Shoulder disarticulation.
  • Lower-limb amputation.
  • Temporary prosthesis.
  • Major expected routine activity change.
  • Progressive pathology preventing follow-up.
Show all 10Show fewer
  • Pregnancy.
  • Protected/vulnerable adults.
  • No health insurance affiliation.
  • Unable to understand study instructions.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • Multiple facilities

    Multiple Locations

    Emma Blundell Emma, +64 22 571 1479, emma.blundell@taskaprosthetics.com

    Recruiting

Other trials in France

About this study

Official title: Prospective Multicentre Randomized Cross-Over Study Evaluating Specific Function of Upper-Limb Amputee Patients Using the Multi-Grip Myoelectric Hand Prosthesis GEN2 Versus Other Multi-Grip Myoelectric Hand Prostheses

This prospective multicentre randomized cross-over post-market clinical follow-up study compares the TASKA GEN2 multi-grip myoelectric hand prosthesis with marketed comparator prostheses in adults with upper-limb amputation. The study evaluates specific function using the Patient-Specific Functional Scale together with upper-limb function, comfort, quality of life, satisfaction and safety outcomes.

Read the detailed description

Upper-limb amputation significantly impairs daily activities and quality of life. Multi-grip myoelectric hand prostheses may improve upper-limb function compared with standard prostheses. This study compares the CE-marked TASKA GEN2 prosthesis with marketed comparator prostheses (Michelangelo or I-Limb Ultra) in a randomized cross-over design with two 28-day wearing periods. Patients randomized to receive GEN2 during period 2 will additionally continue using GEN2 for 8 weeks to provide longer-term descriptive data. The primary endpoint is the change in Patient-Specific Functional Scale score at the end of each wearing period compared with baseline.

Being tested
TASKA GEN2 Multi-Grip Myoelectric Hand Prosthesis, Michelangelo or I-Limb Ultra multi-grip myoelectric prosthesis
Keywords
myoelectric prosthesis, upper limb amputation, TASKA GEN2, prosthetic hand, PSFS, OPUS, QuickDASH, TAPES-R, QUEST, SHAP

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TASKA GEN2 Multi-Grip Myoelectric Hand ProsthesisDevice

    Participants use the Taska Gen2 multi-grip myoelectric prosthesis

  • Michelangelo or I-Limb Ultra multi-grip myoelectric prosthesisDevice

    Participants use their usual marketed multi-grip myoelectric hand prosthesis (Michelangelo or I-Limb Ultra) during the relevant 28-day study period.

Study groups in NCT07876115
Study groupRoleWhat they receive
Usual Prosthesis Followed by TASKA GEN2OtherParticipants use their usual marketed multi-grip myoelectric hand prosthesis during period 1 followed by the TASKA GEN2 prosthesis during period 2 and the optional 8-week extension.
Receives: Device: TASKA GEN2 Multi-Grip Myoelectric Hand Prosthesis; Device: Michelangelo or I-Limb Ultra multi-grip myoelectric prosthesis
TASKA GEN2 Followed by Usual ProsthesisOtherParticipants use the TASKA GEN2 prosthesis during period 1 followed by their usual marketed multi-grip myoelectric hand prosthesis during period 2.
Receives: Device: TASKA GEN2 Multi-Grip Myoelectric Hand Prosthesis; Device: Michelangelo or I-Limb Ultra multi-grip myoelectric prosthesis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Patient-Specific Functional Scale (PSFS).

    The Patient-Specific Functional Scale (PSFS) assesses the participant's ability to perform three individually selected daily activities. Each activity is rated from 0 (unable to perform the activity) to 10 (able to perform the activity without restriction).

    The overall PSFS score is calculated as the mean of the three activity scores, ranging from 0 to 10, with higher scores indicating better functional ability.

    The outcome is the change in the overall PSFS score from baseline to the end of each 28-day prosthesis wearing period (end-of-period score minus baseline score). The change ranges from -10 to +10, with positive values indicating improvement.

    Measured: End of each 28-day wearing period

Secondary outcomes (10)
  1. Socket comfort score

    Comfort assessed on an 11-point numeric scale from 0 (most uncomfortable socket imaginable) to 10 (most comfortable socket imaginable)

    Measured: End of each 28-day wearing period

  2. Upper limb function using OPUS status

    OPUS Upper Extremity Functional Status module assesses the participant's perceived ease in performing activities of daily living with the prosthesis. Item responses generate an OPUS raw score, which will be converted according to the OPUS Scoring Guide to a Rasch measure on a 0-to-100 scale. Higher Rasch scores indicate better perceived upper-limb function.

    Measured: : End of each 28-day wearing period

  3. Upper-limb symptoms and disability using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) score.

    The QuickDASH is an 11-item questionnaire assessing symptoms and functional limitations involving the upper limb. Items are rated from 1 (best) to 5 (worst). The score is transformed to a 0-to-100 scale; higher scores indicate greater disability

    Measured: End of each 28-day wearing period

  4. OPUS Health-Related Quality of Life score at the end of each wearing period

    The 23-item OPUS Health-Related Quality of Life component assesses health-related quality of life. Item responses generate a raw score ranging from 0 to 92, which will be converted according to the OPUS Scoring Guide to a Rasch measure on a 0-to-100 scale. Higher Rasch scores indicate better health-related quality of life.

    Measured: End of each 28-day wearing period

  5. Adjustment to amputation and prosthesis using the Trinity Amputation and Prosthesis Experience Scales-Revised (TAPES-R).

    The 33-item TAPES-R assesses three domains: psychosocial adjustment (15 items, rated 1 to 4; higher scores indicate better adjustment), activity restriction (10 items, rated 0 to 2; higher scores indicate greater limitation), and satisfaction with the prosthesis (8 items, rated 1 to 3; higher scores indicate greater satisfaction). Psychosocial adjustment includes general, social, and adjustment-to-limitation subscales; prosthesis satisfaction includes aesthetic and functional subscales.

    Measured: End of each 28-day wearing period.

  6. Satisfaction with the prosthesis using the Evaluation de la Satisfaction envers une Aide Technique (ESAT), French version of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST).

    The ESAT/QUEST contains 12 items rated from 1 (not satisfied at all) to 5 (very satisfied): 8 items assess satisfaction with the technology and 4 assess satisfaction with related services. The total score and the two component scores will be calculated. The summed total score ranges from 12 to 60, with higher scores indicating greater satisfaction. Sources of dissatisfaction are also recorded qualitatively.

    Measured: End of each 28-day wearing period.

  7. Number of Participants Preferring TASKA GEN2 or Their Usual Myoelectric Hand Prosthesis

    At the end of the comparative cross-over phase, participants are asked to indicate which of the two multi-grip myoelectric hand prostheses they prefer: TASKA GEN2 or their usual prosthesis (Michelangelo or I-Limb Ultra).

    The number and percentage of participants preferring each prosthesis will be reported. Percentages will be calculated based on the number of participants who completed the preference assessment.

    Measured: End of period 2 (after two 28-day wearing periods).

  8. Number of days of prosthesis unavailability.

    For each prosthesis wearing period, the number of days during which the allocated prosthesis is unavailable for use is recorded.

    Measured: During each 28-day wearing period.

  9. Number and description of adverse events, serious adverse events, and device deficiencies.

    Safety is assessed by recording adverse events, serious adverse events, and device deficiencies occurring during study participation. The number and detailed description of events and deficiencies will be reported.

    Measured: From enrollment through the participant's final study visit; up to approximately 16 weeks for participants entering the 8-week GEN2 extension

  10. Hand function using the Southampton Hand Assessment Procedure (SHAP) (optional, at centres with SHAP scoring software)

    The SHAP is a clinically validated, timed hand-function test comprising 26 tasks (abstract objects and activities of daily living), each classified into one of six prehensile patterns. Task times are normalised to generate a SHAP Index of Function and a Functionality Profile. A score of 100 corresponds to normal hand function; lower scores indicate greater impairment, and scores above 100 are possible

    Measured: End of each 28-day wearing period]

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Oct 2026
  2. Study start13 Jun 2025
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07876115
Sponsor's protocol ID
2024-A02363-44
Status last verified
Oct 2026
First submitted
4 Oct 2026
Last updated
15 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in